Trofinetide, sold under the brand name Daybue, is a medication used for the treatment of Rett syndrome.[1] It is taken by mouth.[1]
Clinical data | |
---|---|
Trade names | Daybue |
Other names | NNZ-2566 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a623019 |
License data |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 84% |
Metabolism | Insignificant |
Elimination half-life | ~ 1.5 h |
Excretion | Urine |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C13H21N3O6 |
Molar mass | 315.326 g·mol−1 |
3D model (JSmol) |
|
| |
|
The most common adverse reactions include diarrhea and vomiting.[2]
Trofinetide was approved for medical use in the United States in March 2023.[1][2][3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[4]
Trofinetide is indicated for the treatment of Rett syndrome in people two years of age and older.[1][5]
Rett syndrome is a rare, genetic neurological and developmental disorder that affects the way the brain develops.[2] People with Rett syndrome experience a progressive loss of motor skills and language.[2] Most babies with Rett syndrome seem to develop as expected for the first six months of life.[2] These babies then lose skills they previously had attained at approximately six to 18 months of age — such as the ability to crawl, walk, communicate, or use their hands.[2] The hallmark of Rett syndrome is near constant repetitive hand movements, such as rubbing or clapping.[2] Rett syndrome leads to severe impairments affecting nearly every aspect of life, including the ability to speak, walk, eat, and breathe.[2]
It was developed by Neuren Pharmaceuticals that acts as an analogue of the neuropeptide (1-3) IGF-1, which is a simple tripeptide with sequence Gly-Pro-Glu obtained by enzymatic cleavage of the growth factor IGF-1 within the brain. Trofinetide has anti-inflammatory properties and was originally developed as a potential treatment for stroke,[6][7] but has subsequently been developed for other applications and is now approved by the FDA as an oral solution. It has successfully completed Phase III clinical trial against Rett syndrome.[8] Trofinetide has also had a successful Phase II trial against Fragile X syndrome.[9][10][11] The drug is manufactured by Acadia Pharmaceuticals.[citation needed]
The US Food and Drug Administration (FDA) evaluated the efficacy and safety of trofinetide based on a randomized, double-blind, placebo-controlled, 12-week study (Study 1; NCT04181723) of participants with Rett syndrome five to 20 years of age.[2] Participants were randomized to receive trofinetide (N=93) or matching placebo (N=94) for 12 weeks.[2] The dose of trofinetide was based on participant weight to achieve similar exposure in all participants.[2]
The FDA granted the application for trofinetide priority review, orphan drug, and fast track designations.[2]